Cortical and subcortical glutathione levels in adults with autism spectrum disorder by Durieux, Alice M. S. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1002/aur.1522
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Durieux, A. M. S., Horder, J., Hernandez, M. A., Egerton, A., Williams, S. C. R., Wilson, C. E., ... McAlonan, G.
M. (2015). Cortical and subcortical glutathione levels in adults with autism spectrum disorder. Autism research.
10.1002/aur.1522
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
RESEARCH ARTICLE
Cortical and Subcortical Glutathione Levels in Adults
with Autism Spectrum Disorder
Alice M.S. Durieux,* Jamie Horder,* M. Andreina Mendez, Alice Egerton, Steven C. R. Williams,
C. Ellie Wilson, Debbie Spain, Clodagh Murphy, Dene Robertson, Gareth J. Barker,
Declan G. Murphy, and Grainne M. McAlonan
Increased oxidative stress has been postulated to contribute to the pathogenesis of autism spectrum disorder (ASD).
However, reports of alterations in oxidation markers including glutathione (GSH), the major endogenous antioxidant,
are indirect, coming from blood plasma level measurements and postmortem studies. Therefore we used in-vivo 3
Tesla proton magnetic resonance spectroscopy ([1H]MRS) to directly measure GSH concentrations in the basal ganglia
(BG) and the dorsomedial prefrontal cortex of 21 normally intelligent adult males with ASD and 29 controls who did
not differ in age or IQ. There was no difference in brain GSH between patients and controls in either brain area; nei-
ther did GSH levels correlate with measures of clinical severity in patients. Thus [1H]MRS measures of cortical
and subcortical GSH are not a biomarker for ASD in intellectually able adult men. Autism Res 2016, 9: 429–435.
VC 2015 The Authors Autism Research published by Wiley Periodicals, Inc. on behalf of International Society for
Autism Research.
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Introduction
Autism spectrum disorder (ASD) is a neurodevelopmen-
tal condition characterized by repetitive behaviors and
impairments in reciprocal social interactions and com-
munication [American Psychiatric Association, 2013],
affecting about 1% of the population [Baron-Cohen
et al., 2009].
The aetiology of ASD remains unclear, though various
genetic, environmental and immunological factors are
thought to influence the development of the disorder
[Deth, Muratore, Benzecry, Power-Charnitsky, & Waly,
2008]. Among these, oxidative stress—particularly that
arising from toxic environmental exposures—has been
proposed to play a central role in its pathogenesis
[Chauhan & Chauhan, 2006; Deth et al., 2008; Deth,
2013; Theoharides, Kempuraj, & Redwood, 2009]. This
“Redox Hypothesis” is supported by reports of increased
markers of oxidative stress and lipid peroxidation in
individuals with ASD, including elevated red blood cell
nitric oxide, decreased plasma levels of antioxidant
proteins, and an imbalance between the reduced and
oxidised forms of glutathione (GSH) [Chauhan, Chau-
han, Brown, & Cohen, 2004; Kern & Jones, 2006].
GSH is the major endogenous cellular antioxidant. It
protects against lipid peroxidation and oxidative stress, by
maintaining the balance between production and
removal of reactive oxygen species (ROS) [Shimizu et al.,
1998]. Lower levels of GSH and higher levels of its oxi-
dized metabolite, GSSG, have been reported in the plasma
of individuals with ASD and this has been suggested to
indicate greater oxidative stress [Frustaci et al., 2012; Geier
et al., 2009; James et al., 2004; Main, Angley, O’Doherty,
Thomas, & Fenech, 2012]. However, it is unclear whether
this decrease in peripheral GSH also occurs in the brain.
Decreased GSH, increased GSSG, and a decreased
GSH:GSSG ratio have been reported in the cerebellum and
temporal cortex of subjects with ASD post-mortem
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[Chauhan, Audhya, & Chauhan, 2012]. However, post-
mortem studies are limited by the quality of protein pres-
ervation [Ferrer, Martinez, Boluda, Parchi, & Barrachina,
2008], therefore GSH concentrations in the ASD brain also
need to be researched in vivo.
Brain GSH can be measured in vivo using the tech-
nique of proton magnetic resonance spectroscopy
([1H]MRS). This approach has been applied to individu-
als with various neuropsychiatric disorders using a 3T
scanner. For instance, temporal cortex GSH levels have
been reported to be higher in people with psychosis,
whereas no difference in brain GSH has been found in
those with bipolar disorder [Godlewska, Yip, Near,
Goodwin, & Cowen, 2014; Lagopoulos et al., 2013;
Wood et al., 2009]. However to date, no-one has exam-
ined [1H]MRS measures of GSH in ASD.
Therefore, in this study, we compared brain GSH in
unmedicated adult men with ASD and healthy controls of
similar age and IQ using [1H]MRS. [1H]MRS spectra were
acquired in the basal ganglia (BG) and in the dorsomedial
prefrontal cortex (DMPFC). These regions were chosen
because they have been consistently reported to have
both structural abnormalities and functional deficits (rele-
vant to the core symptoms) in ASD (e.g. see [Haznedar
et al., 2006; Hollander et al., 2005; Horder et al., 2013;
Schmitz, Daly, & Murphy, 2007]. For instance, anomalies
in the BG are thought to be responsible for repetitive
behaviors [Hollander et al., 2005; Naaijen, Lythgoe, Amiri,
Buitelaar, & Glennon, 2015], while frontal network defi-
cits have been implicated in social symptoms [Bernhardt
et al., 2014; Watanabe et al., 2012; Wicker et al., 2008].
We tested the hypotheses that men with ASD have lower
GSH than controls and that this would correlate with the
severity of ASD symptoms [assessed using the Autism
Observation Schedule (ADOS) [Lord, Rutter, DiLavore, &
Risi, 1999] and the Autism Diagnostic Interview—Revised
(ADI) [Lord, Rutter, & Le Couteur, 1994] for current and
past symptoms respectively]. As co-morbid symptoms of
anxiety, depression and ADHD are common in ASD [Mat-
son & Cervantes, 2014; Mazzone, Ruta, & Reale, 2012], we
also explored potential correlations between GSH levels
and symptoms rated using the State-Trait Anxiety Inven-
tory (STAI) [Ferreira & Murray, 1983], the Beck depression
inventory (BDI) [Beck, Ward, Mendelson, Mock, &
Erbaugh, 1961] and the Barkley self-reported childhood
and adulthood scales (BSSR-Child and BSSR-Adult) [Bark-
ley & Murphy, 1998], respectively.
Materials and methods
Participants
Twenty one male participants with ASD and 29 healthy
men who did not differ in IQ or age were included in
this study. Participants were aged 18–50. All participants
were right handed and had not been taking
psychoactive medication for at least six weeks prior to
the study. Full scale IQ was assessed by a trained
researcher using the Wechsler Abbreviated Scale of Intel-
ligence [Rudie et al. 2013]. Only participants with
IQ>80 were included in this study. Participants with
ASD were recruited from the Behavioural Genetics Clinic
at the Maudsley Hospital, a specialist adult autism diag-
nostic clinic. All had been diagnosed with autism by
experienced psychiatrists according to the ICD-10 crite-
ria (2009). The diagnosis was confirmed using the ADI
and/or ADOS. We excluded individuals with a comorbid
psychotic illness, epilepsy, a history of head injury, or a
genetic disorder (e.g., Fragile X syndrome) known to be
associated with ASD. Symptoms of anxiety, depression
and attention deficit and hyperactivity disorder (ADHD)
were measured using the STAI [Ferreira & Murray, 1983],
the BDI and the BSSR-Child and BSSR-Adult scales
respectively. All participants provided written informed
consent to participate. This study was approved by Essex
2 National Research Ethics Committee.
[1H]MRS Data Acquisition and Processing
[1H] MRS data were acquired on a 3T GE HDx MRI
scanner (GE Medical Systems, Milwaukee, WI, USA). A
structural MRI scan for subsequent voxel positioning
was acquired using a 3D fast inversion-recovery pre-
pared gradient echo acquisition with TI5450 ms,
TR57 ms, TE52.8 ms, matrix5256 3 256 over a 240
3 240 mm field of view, giving a 0.9375 3 0.9375 mm
in plane voxel size, 124 3 1.1 mm slices (partitions).
[1H]MRS spectra were acquired using point-resolved
spectroscopy (PRESS) [Bottomley, 1987]. One voxel (20
3 20 3 15 mm3) was placed in the left basal ganglia
(BG), including the head of the caudate, the anterior
putamen, and the internal capsule. Another voxel (16
3 24 3 20 mm3) was placed in the left DMPFC (see Fig.
1). PRESS parameters were: TR53000 ms, TE530 ms.
One hundred twenty-eight averages were collected in
the BG voxel and 96 in the DMPFC voxel. [1H]MRS
spectra were processed using LCModel software version
6.3-0I [Provencher, 1993].
Data were analysed with a basis set optimized for the
detection of glutathione, which also included the fol-
lowing metabolites: alanine, aspartate, creatine,
gamma-aminobutyric acid (GABA), glutamine, gluta-
mate, GSH, glucose, glycerophosphocholine, phospho-
choline, phosphocreatine, myo-inositol (mI), lactate, N-
acetyl-aspartate (NAA), N-acetyl-aspartylglutamate
(NAAG), scyllo-inositol, and taurine. However, only
GSH was considered here.
Spectra were first reviewed visually to verify that spec-
tra were not qualitatively abnormal. Poorly fitted
metabolite estimates, defined as Cramer-Rao lower
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bounds (CRLB) >20%, were excluded from further
analysis.
Calculation of GSH Concentrations
To control for inter-individual differences in voxel tis-
sue composition, the proportion of grey matter (GM),
white matter (WM), and cerebrospinal fluid (CSF) in
each voxel was calculated. This method provides a use-
ful alternative to reporting metabolite concentrations as
ratios to Creatine content [Brooks et al., 2001; Gussew,
Erdtel, Hiepe, Rzanny, & Reichenbach, 2012]. The struc-
tural MRI was segmented into GM, WM and CSF using
Statistical Parametric Mapping software (SPM2; http://
spm.ion.ucl.ac.uk) and percent tissue class of each voxel
was calculated using in-house software as previously
described [Horder et al., 2013]. Raw metabolite values
were corrected for CSF as follows:
GSHcorrected5 GSHRaw=ð12ProportionCSFÞ
Where ProportionCSF ranged between 0 and 1, and
was calculated individually for each voxel. Raw metabo-
lite values corrected for CSF are referred to as corrected
GSH concentrations in the rest of this article.
Statistical Analysis
All data were analysed in IBM SPSS 21. Group differen-
ces in demographic variables and symptom severity
were determined using independent sample t-tests. To
investigate potential differences in GSH between
groups, we used a general linear model with corrected
GSH concentrations as the dependent variable, group as
a between subjects factor, and age as covariate, to
account for any GSH variation with age [Currais &
Maher, 2013; Maurya & Rizvi, 2010].
The relationship between GSH and the severity of
current ASD symptoms measured using the three sub-
scales of the ADOS, of past ASD symptoms (three sub-
scales of the ADI) and of anxiety, depression and ADHD
symptoms (STAI, BDI, BSSR child and adult scales) was
assessed using Pearson correlation coefficient or Spear-
man’s rank correlation coefficient, depending on the
data distribution. To account for multiple comparisons
in these analyses, we used a “family wise” error correc-
tion. The P-value threshold of 0.05 was divided by 3 for
analyses of correlations with three subscales of the
ADOS; it was also divided by 3 for analyses of correla-
tions with three subscales of the ADI; and it was
divided by 4 for analyses of correlations with four
comorbid symptom ratings.
Results
Participants
There was no significant difference in age or IQ
between the ASD and control groups. As expected, the
participants with ASD scored higher than controls on
the questionnaire measures of depression, anxiety, and
attention-deficit disorder symptoms (all F>4.7, all
P<0.04). Participant characteristics are summarised in
Table I. After excluding spectra where the uncertainty
(% CRLB) of the GSH estimates were greater than 20%
the sample size was 13 patients and 19 controls for the
DMPFC voxel, and 16 patients and 18 controls for the
BG voxel.
Glutathione
There was no significant effect of group on corrected
GSH concentrations in either voxel (F<0.9, P>0.1);
Figure 1. Example of the location of the proton magnetic resonance spectroscopy voxel in the dorsomedial prefrontal cortex (a),
and in the basal ganglia (b).
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neither was there a main effect of age, or an interaction
between group and age. The results were unchanged
when GSH was examined as a ratio to total Creatine (all
P>0.3). Mean corrected GSH concentrations are shown
in Figure 2.
Correlations with Symptom Measures
In the ASD group there were no significant correlations
between GSH concentrations in either voxel and scores
on the ADOS, the ADI, the BDI, the STAI and the BSSR
scales.
Tissue Composition and Data Quality
There was no significant group difference in percentage
of grey matter, white matter or CSF in either voxel. Fig-
ure 3 shows an example of [1H]MRS spectrum after
LCModel 6.3-0I fitting.
Discussion
This is the first study to quantify glutathione (GSH)
brain concentrations in vivo in unmedicated adult men
with ASD compared to healthy controls. We observed
no group differences in GSH concentrations in either
the basal ganglia or the dorsomedial prefrontal cortex
and no relationship between GSH levels and clinical
symptoms.
Our finding contrasts with prior investigations that
have reported decreased GSH in blood plasma in ASD
[James et al., 2004], however, it is consistent with post-
mortem evidence reporting no difference in GSH in the
frontal cortex of individuals with ASD [Chauhan et al.,
2012]. Thus, our findings do not support the hypothesis
that neuronal damage, secondary to oxidative stress
caused by deficient GSH contributes to ASD pathogene-
sis [Deth et al., 2008; Main et al., 2012].
We emphasize that our study included only right
handed males with normal intelligence. Therefore, it
remains possible that GSH abnormalities exist in other
subgroups of individuals with ASD, for example,
women, or those with intellectual disability. Age may
be especially important to consider in this context
because GSH levels have been reported to vary in other
age groups [Currais & Maher, 2013; Maurya & Rizvi,
2010]. For example, prior investigations have found
that GSH is significantly lower in children with ASD
[Chauhan et al., 2012; Frustaci et al., 2012; James et al.,
2004]. Future longitudinal studies are needed to address
this.
Alternatively, it is possible that a difference in GSH
concentrations does exist in the population that we
studied, but that we were unable to detect it (Type II
Figure 2. Mean corrected glutathione concentrations in the dorsomedial prefrontal cortex and the basal ganglia did not differ sig-
nificantly between groups. Error bars represent the standard error of the mean. (GSH, Glutathione; BG, Basal Ganglia; DMPFC, Dorso-
medial Prefrontal Cortex).
Table I. Participant Characteristics
Characteristic ASD Patients Healthy controls
Age 31.82 (8.63) 26.94 (7.39)
ADOS Social behavior 16.47 (5.97) Not applicable
Communication 12.49 (7.26) Not applicable
ADI Social behavior 16.47 (5.97) Not applicable
Communication 12.49 (7.26) Not applicable
Repetitive behavior 4.67 (2.94) Not applicable
BDI 8.97 (10.23) 3.00 (4.43)
STAI 52.19 (12.90) 35.29 (8.88)
BSSR Childhood scale 6.35 (5.04) 1.95 (2.01)
BSSR Adulthood scale 3.60 (3.62) 1.50 (1.58)
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error). Our sample size was modest, reflecting our deci-
sion to limit our sample to those individuals who were
not taking any medications that might affect brain
chemistry. However, our sample size was similar to that
of Wood et al. [2009] who found a robust 22% differ-
ence in GSH concentrations at threshold of P<0.05
using similar approaches in individuals with schizo-
phrenia, and larger than that of Godlewska et al. [2014]
who found no difference in GSH concentrations
between bipolar participants and healthy controls. In
addition, a post hoc power calculation based on the
present data confirmed that if any group differences do
exist these are likely to be extremely small and there-
fore arguably trivial; as a total sample size of at least
n51200 would be necessary for detection (80% power,
at P<0.05).
Our study has a number of other limitations. We did
not exclude participants with co-morbid anxiety, depres-
sion and ADHD symptoms, but we measured these symp-
toms using validated clinical scales. We found that ASD
participants had higher levels of symptoms than con-
trols. However this was not unexpected. These are very
common comorbidities in ASD and a sample without
any comorbid disorders would be quite unrepresentative
for the spectrum [Mazzone et al., 2012].
From a methodological perspective, GSH is often
quantified using a J-edited MEGAPRESS sequence with a
longer echo time (TE), but we employed a short TE
PRESS sequence to quantify GSH. However, others have
shown that GSH can be measured using PRESS at simi-
lar echo times [Lagopoulos et al., 2013; Wood et al.,
2009]. While the test-retest reliability of PRESS GSH
estimates have never been specifically investigated,
PRESS is known to provide reliable quantification for
other common metabolites [Fayed, Modrego, &
Medrano, 2009].
A further consideration is that we investigated only
the basal ganglia and the dorsomedial prefrontal cortex
and differences in GSH might yet be found in other
brain areas. For example, lower levels of GSH in ASD
have been reported in the temporal lobe and cerebel-
lum postmortem [Chauhan et al., 2012]. Indeed, con-
centration differences in other brain metabolites are
known to be regionally specific in ASD [Horder et al.,
2013]. Finally, we did not measure the oxidised coun-
terpart of GSH, GSSG. Hence we cannot exclude the
possibility that GSSG levels are altered in our ASD sam-
ple, resulting in GSH redox imbalance.
In summary, the data presented here suggest that oxi-
dative stress resulting from low levels of GSH is not a
feature of adult men with normal IQ and ASD. How-
ever, we cannot exclude the possibility that further
exploration of GSH in other subgroups of ASD (for
example, those with low IQ), and at different ages, may
help identify individuals who may benefit from anti-
oxidant treatments.
Acknowledgements
A.M.S.D and J.H. contributed equally to this work. The
MRI and MRS data acquisition of this work was funded
by the Wellcome Trust (091300/Z/10/Z). A.M.S.D and
G.M.M. receive support from the National Institute for
Health Research (NIHR) Mental Health Biomedical
Research Centre at South London and Maudsley NHS
Foundation Trust and King’s College London. The views
expressed are those of the authors and not necessarily
those of the NHS, the NIHR or the Department of
Health. The funders had no role in the study design,
data collection, analysis, or decision to submit for pub-
lication. C.M., G.M.M. and D.G.M. are supported by
the Dr Mortimer D. Sackler Foundation and are mem-
bers of the EU-AIMS consortium. GJB received honora-
ria for teaching from General Electric Healthcare during
the course of this study, and acts as a consultant for
IXICO. Ethical approval for this study was provided by
Essex 2 Research Ethics Committee (REC code 04/
Q0102/26).
References
American Psychiatric Association. (2013). Diagnostic and statis-
tical manual of mental disorders, 5th ed. Washington, DC:
Author.
Barkley, R.A., & Murphy, K.R. (1998). Attention-deficit hyper-
activity disorder: A Handbook for Diagnosis and Treatment
(2nd ed.). New York: Guilford Press.
Baron-Cohen, S., Scott, F.J., Allison, C., Williams, J., Bolton, P.,
Matthews, F.E., et al. (2009). Prevalence of autism-spectrum
conditions: UK school-based population study. British Jour-
nal of Psychiatry, 194, 500–509.
Figure 3. Example of a proton magnetic resonance spectros-
copy spectrum after LCModel 6.3-0I fitting.
INSAR Durieux et al./Glutathione in Autism 433
Beck, A.T., Ward, C.H., Mendelson, M., Mock, J., & Erbaugh, J.
(1961). An inventory for measuring depression. Archives of
General Psychiatry, 4, 561–571.
Bernhardt, B.C., Valk, S.L., Silani, G., Bird, G., Frith, U., &
Singer, T. (2014). Selective disruption of sociocognitive
structural brain networks in autism and alexithymia. Cere-
bral Cortex, 24, 3258–3267.
Bottomley, P.A. (1987). Spatial localization in NMR spectros-
copy in vivo. Annals of the New York Academy of Sciences,
508, 333–348.
Brooks, J.C., Roberts, N., Kemp, G.J., Gosney, M.A., Lye, M., &
Whitehouse, G.H. (2001). A proton magnetic resonance
spectroscopy study of age-related changes in frontal lobe
metabolite concentrations. Cerebral Cortex, 11, 598–605.
Chauhan, A., Audhya, T., & Chauhan, V. (2012). Brain region-
specific glutathione redox imbalance in autism. Neuro-
chemical Research, 37, 1681–1689.
Chauhan, A., & Chauhan, V. (2006). Oxidative stress in
autism. Pathophysiology, 13, 171–181.
Chauhan, A., Chauhan, V., Brown, W.T., & Cohen, I. (2004).
Oxidative stress in autism: increased lipid peroxidation and
reduced serum levels of ceruloplasmin and transferrin–the
antioxidant proteins. Life Science, 75, 2539–2549.
Currais, A., & Maher, P. (2013). Functional consequences of
age-dependent changes in glutathione status in the brain.
Antioxidants and Redox Signaling, 19, 813–822.
Deth, R., Muratore, C., Benzecry, J., Power-Charnitsky, V.A., &
Waly, M. (2008). How environmental and genetic factors
combine to cause autism: A redox/methylation hypothesis.
Neurotoxicology, 29, 190–201.
Deth, R.C. (2013). Autism: A redox/methylation disorder.
Global Advances in Health and Medicine, 2, 68–73.
Fayed, N., Modrego, P.J., & Medrano, J. (2009). Comparative
test-retest reliability of metabolite values assessed with mag-
netic resonance spectroscopy of the brain. The LCModel
versus the manufacturer software. Neurological Research,
31, 472–477.
Ferreira, R., & Murray, J. (1983). Spielberger’s State-Trait Anxi-
ety Inventory: Measuring anxiety with and without an
audience during performance on a stabilometer. Perceptual
and Motor Skills, 57, 15–18.
Ferrer, I., Martinez, A., Boluda, S., Parchi, P., & Barrachina, M.
(2008). Brain banks: Benefits, limitations and cautions con-
cerning the use of post-mortem brain tissue for molecular
studies. Cell and Tissue Banking, 9, 181–194.
Frustaci, A., Neri, M., Cesario, A., Adams, J.B., Domenici, E.,
Dalla Bernardina, B., et al. (2012). Oxidative stress-related
biomarkers in autism: systematic review and meta-analyses.
Free Radical Biology and Med, 52, 2128–2141.
Geier, D.A., Kern, J.K., Garver, C.R., Adams, J.B., Audhya, T.,
Nataf, R., et al. (2009). Biomarkers of environmental toxic-
ity and susceptibility in autism. Journal of Neurological Sci-
ence, 280, 101–108.
Godlewska, B.R., Yip, S.W., Near, J., Goodwin, G.M., & Cowen,
P.J. (2014). Cortical glutathione levels in young people with
bipolar disorder: a pilot study using magnetic resonance
spectroscopy. Psychopharmacology (Berl), 231, 327–332.
Gussew, A., Erdtel, M., Hiepe, P., Rzanny, R., & Reichenbach,
J.R. (2012). Absolute quantitation of brain metabolites with
respect to heterogeneous tissue compositions in (1)H-MR
spectroscopic volumes. MAGMA, 25, 321–333.
Haznedar, M.M., Buchsbaum, M.S., Hazlett, E.A., LiCalzi,
E.M., Cartwright, C., & Hollander, E. (2006). Volumetric
analysis and three-dimensional glucose metabolic map-
ping of the striatum and thalamus in patients with
autism spectrum disorders. American Journal of Psychia-
try, 163, 1252–1263.
Hollander, E., Anagnostou, E., Chaplin, W., Esposito, K.,
Haznedar, M.M., Licalzi, E., et al. (2005). Striatal volume on
magnetic resonance imaging and repetitive behaviors in
autism. Biological Psychiatry, 58, 226–232.
Horder, J., Lavender, T., Mendez, M.A., O’Gorman, R., Daly, E.,
Craig, M.C., et al. (2013). Reduced subcortical glutamate/
glutamine in adults with autism spectrum disorders: A
[(1)H]MRS study. Translational Psychiatry, 3, e279.
James, S.J., Cutler, P., Melnyk, S., Jernigan, S., Janak, L.,
Gaylor, D.W., et al. (2004). Metabolic biomarkers of
increased oxidative stress and impaired methylation
capacity in children with autism. The American Journal of
Clinical Nutrition, 80, 1611–1617.
Kern, J.K., & Jones, A.M. (2006). Evidence of toxicity, oxidative
stress, and neuronal insult in autism. Journal of Toxicology
and Environmental Health Part B Critical Reviews, 9, 485–
499.
Lagopoulos, J., Hermens, D.F., Tobias-Webb, J., Duffy, S.,
Naismith, S.L., White, D., et al. (2013). In vivo glutathione
levels in young persons with bipolar disorder: A magnetic
resonance spectroscopy study. Journal of Psychiatric
Research, 47, 412–417.
Lord, C., Rutter, M., DiLavore, P., & Risi, S. (1999). Autism
Diagnostic Observation Schedule. Los Angeles, California:
Western Psychological Services.
Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism diagnos-
tic interview-revised: A revised version of a diagnostic inter-
view for caregivers of individuals with possible pervasive
developmental disorders. Journal of Autism and Develop-
mental Disorders, 24, 659–685.
Main, P.A., Angley, M.T., O’Doherty, C.E., Thomas, P., &
Fenech, M. (2012). The potential role of the antioxidant
and detoxification properties of glutathione in autism spec-
trum disorders: A systematic review and meta-analysis.
Nutrition and Metabolism (London), 9, 35.
Matson, J.L., & Cervantes, P.E. (2014). Commonly studied
comorbid psychopathologies among persons with autism
spectrum disorder. Research in Developmental Disabilities,
35, 952–962.
Maurya, P.K., & Rizvi, S.I. (2010). Age-dependent changes in
glutathione-s-transferase: Correlation with total plasma
antioxidant potential and red cell intracellular glutathione.
Indian Journal of Clinical Biochemistry, 25, 398–400.
Mazzone, L., Ruta, L., & Reale, L. (2012). Psychiatric comor-
bidities in asperger syndrome and high functioning
autism: diagnostic challenges. Annals of General Psychia-
try, 11, 16.
Naaijen, J., Lythgoe, D.J., Amiri, H., Buitelaar, J.K., & Glennon,
J.C. (2015). Fronto-striatal glutamatergic compounds in
compulsive and impulsive syndromes: A review of magnetic
resonance spectroscopy studies. Neuroscience and Biobeha-
vioral Reviews, 52, 74–88.
434 Durieux et al./Glutathione in Autism INSAR
Provencher, S.W. (1993). Estimation of metabolite concentra-
tions from localized in vivo proton NMR spectra. Magnetic
Resonance in Medicine, 30, 672–679.
Rudie, J.D., Brown, J.A., Beck-Pancer, D., Hernandez, L.M.,
Dennis, E.L., Thompson, P.M., et al. (2013) Altered func-
tional and structural brain network organization in autism.
Neuroimage Clinical, 2, 79–94.
Schmitz, N., Daly, E., & Murphy, D. (2007). Frontal anatomy and
reaction time in Autism. Neuroscience Letters, 412, 12–17.
Shimizu, T., Iwanaga, M., Yasunaga, A., Urata, Y., Goto, S.,
Shibata, S., et al. (1998). Protective role of glutathione syn-
thesis on radiation-induced DNA damage in rabbit brain.
Cellular and Molecular Neurobiology, 18, 299–310.
Theoharides, T.C., Kempuraj, D., & Redwood, L. (2009).
Autism: An emerging ‘neuroimmune disorder’ in search of
therapy. Expert Opinion on Pharmacotherapy, 10, 2127–
2143.
Watanabe, T., Yahata, N., Abe, O., Kuwabara, H., Inoue, H.,
Takano, Y., et al. (2012). Diminished medial prefrontal
activity behind autistic social judgments of incongruent
information. PLoS One, 7, e39561.
Wicker, B., Fonlupt, P., Hubert, B., Tardif, C., Gepner, B., &
Deruelle, C. (2008). Abnormal cerebral effective connectiv-
ity during explicit emotional processing in adults with
autism spectrum disorder. Social Cognitive and Affectve
Neuroscience, 3, 135–143.
Wood, S.J., Berger, G.E., Wellard, R.M., Proffitt, T.M.,
McConchie, M., Berk, M., et al. (2009). Medial temporal lobe
glutathione concentration in first episode psychosis: A 1H-
MRS investigation. Neurobiology of Disease, 33, 354–357.
INSAR Durieux et al./Glutathione in Autism 435
